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I was not much involved in the discussion and debate
about initiating a program to determine the base-pair se-
quence of the human genome, until the idea surfaced pub-
licly. As I recall the genesis of the HumanGenome Project,
the idea for sequencing the human genome was initiated
independently and nearly simultaneously by Robert Sins-
heimer, then Chancellor of the University of California–
Santa Cruz (UCSC), and Charles DeLisi of the United
States Department of Energy. Each had his own purpose
in promoting such an audacious undertaking, but the
goals of their ambitious plans are best left for them to tell.
The proposal was initially aired at a meeting of a small
group of scientists convened by Sinsheimer at UCSC in
May 1985 and received the backing of thosewho attended.
I became aware of the project through an editorial or
op-ed–style piece by Renato Dulbecco in Science, March
1986. Dulbecco’s enthusiasm for the project was based on
his conviction that only by having the complete human
genome sequence could we hope to identify the many
oncogenes, tumor suppressors, and their modiﬁers. Al-
though that particular goal seemed problematic, I was en-
thusiastic about the likelihood that the sequence would
reveal important organizational, structural, and func-
tional features of mammalian genes.
That conviction stemmed from having seen, ﬁrsthand,
the tremendous advantages of knowing the sequence of
SV40 (in 1978) and adenovirus genomic DNAs (in 1979–
1980), particularly for deciphering their biological prop-
erties. In each of these instances, as well as for the longer
and more complex genomic DNAs of the herpes virus and
cytomegalovirus, knowing the sequences was critical for
accurately mapping their mRNAs, identifying the introns,
and making pretty good guesses about the transcriptional
regulatory elements. Even more signiﬁcant was the ability
to engineer precisely targeted modiﬁcations to their ge-
nomes (e.g., base changes, deletions and additions, se-
quence rearrangements, and substitutions of deﬁned seg-
ments with nonviral DNA). One could easily imagine that
knowing the human DNA sequence would enable us to
manipulate the sequences of speciﬁc genes for a variety
of hitherto-undoable experiments.
Aware of the upcoming 1986 Cold Spring Harbor (CSH)
Symposium on the “Molecular Biology of Homo sapiens,”
I suggested to Jim Watson that it might be interesting to
convene a small group of interested people to discuss the
proposal’s feasibility. I thought that such a rump session
might attract people who would be engaged by the pro-
posal, and Watson agreed to set aside some time during
the ﬁrst free afternoon. As the attendees assembled, it was
clear that the project was on the minds of many, and
almost everyone who attended the symposium showed
up for the session at the newly dedicated Grace Audito-
rium.Wally Gilbert and I were assigned the task of guiding
the discussion. Needless to say, what followed was highly
contentious; the reactions ranged from outrage to mod-
erate enthusiasm—the former outnumbering the latter by
about ﬁve to one.
Gilbert began the discussion by outlining his favored
approach: fragment the entire genome’s DNA into a col-
lection of overlapping fragments, clone the individual
fragments, sequence the cloned segments with the then-
existing sequencing technology, and assemble their orig-
inal order with appropriate computer software. In hismost
self-assured manner, Gilbert estimated that such a project
could be completed in ∼10–20 years at a net cost of ∼$1
per base, or ∼$3 billion. Even before he ﬁnished, one could
hear the rumblings of discontent and the audience’s gath-
ering outrage. It was not just his matter-of-fact manner
and self-assurance about his projections that got the dis-
cussion off on the wrong foot, for there was also the rumor
(which may well have been planted by Gilbert) that a
company he was contemplating starting would undertake
the project on its own, copyright the sequence, and mar-
ket its content to interested parties.
One could sense the fury of many in the audience, and
there was a rush to speak out in protest. Among the more
vociferous comments, three points stood out:
1. The cost of doing this project would diminish federal
funding for individual investigator–initiated science
and thereby would shift the culture of basic biolog-
ical research from “Little Science” to “Big Science.”
Some feared that biology would experience the same
consequence that physics did when massive projects
like the Stanford Linear Accelerator Center were un-
dertaken in that ﬁeld.
2. Many thought that Gilbert’s approach was boring
and thus would not attract well-experienced people,
which, most likely, would make the product suspect.
Moreover, the beneﬁts of the sequence project might
not materialize until the very late stages.
3. A surprisingly vocal group argued that, because !5%
of the DNA sequence was informational (i.e., repre-
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sented by genes encoding proteins and RNAs), there
was no point in sequencing what was unaffection-
ately labeled “junk”—junk was deﬁned as all the stuff
between genes and within introns. Why, many
asked, should we spend a lot of money and effort to
sequence what was clearly irrelevant?
The fury of the reactions of some of our most respected
molecular geneticists startled me. Several of the speakers
argued that certain areas of research, usually their own
specialty, were far more valuable than the sequence of the
human genome. I was particularly irked by the claims that
there was no need to sequence the entire 3 billion base
pairs and that knowing the sequences of only the genes
would sufﬁce. Frankly, I was shocked by what seemed to
me to be a display of what I termed an “arrogance of
ignorance.” Why, I asked, should we foreclose on the like-
lihood that noncoding regions within and surrounding
genes contain signals that we have not yet recognized or
learned to assay? Furthermore, wasn’t it conceivable that
there are DNA sequences for functions other than encod-
ing proteins and RNAs? For example, the DNA sequence
might serve for other organismal functions (e.g., chro-
mosomal replication, packaging of the DNA into highly
condensed chromatin, or control of development). It
seemed surprising and disconcerting to hear that many
were prepared to discard, a priori, a potential source of
such information, and it was even more surprising that
this myopic view persisted both throughout the meeting
and for some time afterward.
During the session, I tried to steer the discussion away
from the cost issue and the fuzzy arguments about Little
Science versus Big Science. Perhaps it was better, I thought,
to tempt the creative minds in the audience. After all, this
was a scientiﬁc meeting with some of the most creative
minds sitting in the audience. What if, I said, some phil-
anthropic source descended into our midst and offered $3
billion to produce the sequence of the human genome at
the end of 10 years? And, I suggested, assume that we
were assured that there would be no impact on existing
sources of funding. Would the project be worth doing? If
so, how should we proceed with it? Gilbert had offered
his approach, but, I asked, are there better ways?
To get that discussion started, I proposed that we might
consider sequencing only cloned cDNAs from a variety of
libraries made from different tissues and conditions.
Knowledge of the expressed sequences would enable us
to bootstrap our way to cloning the genomic versions of
the cDNAs and, thereby, enable us to identify the introns
and the likely promoters. Such an approach, I argued,
would very likely yield valuable and interesting cloned
material for many investigators to work on long before
we knew the entire sequence. The premise was that the
effort would identify the chromosomal versions of the
expressed sequences and, with some cleverness, their
ﬂanking sequences.
However, try as I might, I could not engage the audience
in that exercise. Their concerns were about the price that
would be paid by traditional ways of doing science and
that many more-interesting and important problems
would be abandoned or neglected. The meeting ended
with most people unconvinced of the value of proceeding
with a project to sequence the human genome.
At the end of the meeting, I ﬂew to Basel, Switzerland,
where I was part of an advisory group to the Basel Institute
of Immunology. At the hotel, I found a group of American
and European colleagues perched on the veranda over-
looking the fast-ﬂowing Rhine River. They were clearly
aware of the discussion at CSH and my participation in
it. I again had to defend my support for the sequencing
project against arguments that were a repetition of those
expressed at CSH.
Soon thereafter, the National Academy of Sciences con-
vened a blue-ribbon committee, many members of which
had been among the critical voices at CSH. Their report
recast the scope and direction of the project in a more
constructive way; the principal change was the proposal
to proceed in phases: determine the genetic map by use
of principally polymorphic markers, create a physicalmap
consisting of linked cloned cosmids, and focus on devel-
oping more cost- and time-efﬁcient means of sequencing
DNA. The most important recommendation, in my view,
was to include in the project the sequencing of the then-
favorite model organisms: Escherichia coli, Saccharomyces
cerevisiae, Drosophila melanogaster, Caenorhabditis elegans,
and the mouse. It was clear that the new formulation did
not threaten research support for those who worked on
prokaryotes and lower eukaryotes. More likely, the addi-
tional funding would energize research on these organ-
isms. It also provided a livelihood for those interested in
mapping their favorite organism and for those committed
to cloning and mapping large segments of DNA. In the
end, people were molliﬁed by the realization that they
would not be left out of the project’s funding. Also, the
proposal had a logic for how to proceed and the accep-
tance that useful information would be generated long
before the project was completed.
Sometime after the project was under way, Watson be-
came the director of the project and set the agenda for
how the project would proceed. He was committed to a
razor-like focus on the development of genetic and phys-
ical maps, discouraging and even dismissing proposals
that focused on making the work relevant to the biology.
Indeed, that strategy was enforced by the study sections
that reviewed genome-project grant proposals; proposals
involving methods that would further the two mapping
projects received preference, whereas those that hinted at
deviation from that goal went unfunded. There is little
question that Watson’s forceful and committed leadership
ensured the project’s success.
It is interesting, in retrospect, that the course Gilbert
had proposed for obtaining the human genome se-
quence—shotgun cloning, sequencing, and assembly of
completed bits into the whole—was what carried the day.
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Also, people who had dismissed the necessity of knowing
the sequence of the junk now readily admit that the junk
may very well be the crown jewels, the stuff that orches-
trates the coding sequences in biologically meaningful ac-
tivities. The past few years have revealed unexpected ﬁnd-
ings regarding noncoding genomic sequences, giving
assurance that there is much more to discover in the ge-
nome sequences. Moreover, understanding the function
of the noncoding genome sequences is very likely to ac-
celerate, as the tools for mining the sequence and the
application of robust and large-scale methods for detect-
ing transcription become more reﬁned.
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